SUBSCRIBE
SUBSCRIBE
News   Policy

U.S. FDA Staff Eyes Safety of Novartis AG’s MS Drug, Gilenia

June 8, 2010 | 
1 min read
Reuters -- U.S. regulators expressed concern about potential side effects of Novartis AG's multiple sclerosis pill in patients most at risk for complications.
Regulatory
Food and Drug Administration (FDA) Novartis
MORE ON THIS TOPIC
Business growth or increase in professional income, business operations, investment profits or interest on savings, increase in interest rates, businessman holding gold coins forming a growing arrow symbol.
Drug pricing
Pfizer Leads Industry-Wide Surge in Drug Prices for 2026 Despite Political Pressure
January 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
whale watching boat in Iceland, group of people look at whale
Approvals
Vanda Ends 40-Year Motion Sickness Drug Drought With FDA Approval for Nereus
January 2, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Recession arrow, Graph showing business decline on led screen
Complete response letters
FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices
January 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Money or health. Scale of balance between money, dollar and medicine, pill. Cost of health. Compare of price healthcare and healthy. Seesaw between wealth and healthy. Treatment or savings. Vector.
Drug pricing
Trump Administration Reaches Pricing Agreements With 9 More Drugmakers
December 22, 2025
 · 
2 min read
 · 
Nick Paul Taylor